Novel N1-(benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 4, 2003, Pages 693-696

  Curtis, Neil R ^a   Diggle, Helen J ^a   Kulagowski, Janusz J ^a   London, Clare ^a   Grimwood, Sarah ^a   Hutson, Peter H ^a   Murray, Fraser ^a   Richards, Pawel ^a   Macaulay, Alison ^a   Wafford, Keith A ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; N 1 (BENZYL)CINNAMAMIDINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENYL GROUP; RO 256981; TRAXOPRODIL; UNCLASSIFIED DRUG; AMIDINE; BENZAMIDINE DERIVATIVE; BETA NAPHTHAMIDIN; BETA-NAPHTHAMIDINE; NAPHTHALENE DERIVATIVE; NR2B NMDA RECEPTOR;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; DRUG SELECTIVITY; DRUG SYNTHESIS; ELECTROPHYSIOLOGY; IC 50; PATCH CLAMP; DRUG ANTAGONISM; DRUG SCREENING; HUMAN; METABOLISM; PROTEIN BINDING; RADIOASSAY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

AMIDINES; BENZAMIDINES; DRUG EVALUATION, PRECLINICAL; HUMANS; NAPHTHALENES; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037294026     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)01060-0     Document Type: Article

References (12)

1. Dingledine R., Borges K., Bowie D., Traynelis S.F. Pharmacol. Rev. 51:1999;7.
2. Monyer H., Burnashev N., Laurie D.J., Sakmann B., Seeburg P.H. Neuron. 12:1994;529.
3. Boyce S., Wyatt A., Webb J.K., O'Donnell R., Mason G., Rigby M., Sirinathsinghji D., Hill R.G., Rupniak N.M.J. Neuropharmacology. 38:1999;611.
4. Chenard B.L., Menniti F.S. Curr. Pharm. Des. 5:1999;381.
5. Nikam S.S., Meltzer L.T. Curr. Pharm. Des. 8:2002;845.
6. Chizh B.A., Headley P.M., Tzschentke T.M. Trends Pharmacol. Sci. 22:2001;636. and references cited therein.
7. Rousselet G., Capdavielle P., Maumy M. Tetrahedron Lett. 34:1993;6395.
8. Garigipati R.S. Tetrahedron Lett. 31:1990;1969.
9. Grimwood S., Richards P., Murray F., Harrison N., Wingrove P.B., Hutson P.H. J. Neurochem. 75:2000;2455.
10. Priestley T., Laughton P., Myers J., Le Bourdelles B., Kerby J., Whiting P.J. Mol. Pharmacol. 48:1995;841.
11. Claiborne, C. F.; McCauley, J. A.; Libby, B. E.; Curtis, N. R.; Diggle, H. J.; Kulagowski, J. J; Michelson, S. R.; Anderson, K. D.; Claremon, D. A.; Freidinger, R. M.; Bednar, R. A.; Mosser, S. D.; Gaul, S. L.; Connolly, T. M.; Condra, C. L.; Bednar, B.; Stump, G. L.; Lynch, J. J.; Macaulay, A.; Wafford, K. A.; Koblan, K. S.; Liverton, N. J. Bioorg. Med. Chem. Lett. see following communication. doi:10.1016/S0960-894X(02)01061-2.
12. i 3.2 μM. N-(Phenylalkyl)cinnamide NR2B subtype-selective antagonists have been reported; J. Med. Chem. 1999, 42, 3412.